KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis

FRA:PHI1 • NL0000009538

26.41 EUR
-0.35 (-1.31%)
Last: Feb 13, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

3

Taking everything into account, PHI1 scores 3 out of 10 in our fundamental rating. PHI1 was compared to 65 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of PHI1 have multiple concerns. PHI1 has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • PHI1 had positive earnings in the past year.
  • In the past year PHI1 had a positive cash flow from operations.
  • In multiple years PHI1 reported negative net income over the last 5 years.
  • PHI1 had a positive operating cash flow in 4 of the past 5 years.
PHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFPHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 3.32%, PHI1 is in line with its industry, outperforming 48.44% of the companies in the same industry.
  • PHI1 has a Return On Equity of 8.17%. This is comparable to the rest of the industry: PHI1 outperforms 56.25% of its industry peers.
  • PHI1 has a Return On Invested Capital of 5.16%. This is comparable to the rest of the industry: PHI1 outperforms 42.19% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for PHI1 is significantly below the industry average of 9.57%.
  • The last Return On Invested Capital (5.16%) for PHI1 is above the 3 year average (3.24%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROIC 5.16%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.24%
ROIC(5y)N/A
PHI1.DE Yearly ROA, ROE, ROICPHI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • PHI1 has a Profit Margin of 5.02%. This is comparable to the rest of the industry: PHI1 outperforms 46.88% of its industry peers.
  • PHI1's Profit Margin has declined in the last couple of years.
  • PHI1's Operating Margin of 7.98% is in line compared to the rest of the industry. PHI1 outperforms 42.19% of its industry peers.
  • PHI1's Operating Margin has declined in the last couple of years.
  • The Gross Margin of PHI1 (45.18%) is worse than 75.00% of its industry peers.
  • In the last couple of years the Gross Margin of PHI1 has remained more or less at the same level.
Industry RankSector Rank
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
OM growth 3YN/A
OM growth 5Y-5.59%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
PHI1.DE Yearly Profit, Operating, Gross MarginsPHI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PHI1 is destroying value.
  • PHI1 has more shares outstanding than it did 1 year ago.
  • PHI1 has more shares outstanding than it did 5 years ago.
  • PHI1 has a worse debt/assets ratio than last year.
PHI1.DE Yearly Shares OutstandingPHI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
PHI1.DE Yearly Total Debt VS Total AssetsPHI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.2 Solvency

  • PHI1 has a debt to FCF ratio of 16.37. This is a negative value and a sign of low solvency as PHI1 would need 16.37 years to pay back of all of its debts.
  • PHI1 has a Debt to FCF ratio (16.37) which is comparable to the rest of the industry.
  • PHI1 has a Debt/Equity ratio of 0.63. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
  • PHI1's Debt to Equity ratio of 0.63 is on the low side compared to the rest of the industry. PHI1 is outperformed by 68.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Altman-Z N/A
ROIC/WACC0.8
WACC6.42%
PHI1.DE Yearly LT Debt VS Equity VS FCFPHI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

2.3 Liquidity

  • PHI1 has a Current Ratio of 1.32. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
  • PHI1 has a Current ratio of 1.32. This is comparable to the rest of the industry: PHI1 outperforms 40.63% of its industry peers.
  • PHI1 has a Quick Ratio of 1.32. This is a bad value and indicates that PHI1 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • PHI1 has a worse Quick ratio (0.94) than 64.06% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.94
PHI1.DE Yearly Current Assets VS Current LiabilitesPHI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 12.45% over the past year.
  • PHI1 shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -5.53% yearly.
  • Looking at the last year, PHI1 shows a decrease in Revenue. The Revenue has decreased by -1.04% in the last year.
  • PHI1 shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.59% yearly.
EPS 1Y (TTM)12.45%
EPS 3Y17.92%
EPS 5Y-5.53%
EPS Q2Q%15.25%
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%-1.22%

3.2 Future

  • Based on estimates for the next years, PHI1 will show a small growth in Earnings Per Share. The EPS will grow by 7.17% on average per year.
  • PHI1 is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.79% yearly.
EPS Next Y-2.32%
EPS Next 2Y5.02%
EPS Next 3Y13.51%
EPS Next 5Y7.17%
Revenue Next Year2.83%
Revenue Next 2Y3.55%
Revenue Next 3Y4.91%
Revenue Next 5Y3.79%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PHI1.DE Yearly Revenue VS EstimatesPHI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B 20B 25B
PHI1.DE Yearly EPS VS EstimatesPHI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 16.93, the valuation of PHI1 can be described as correct.
  • Compared to the rest of the industry, the Price/Earnings ratio of PHI1 indicates a rather cheap valuation: PHI1 is cheaper than 85.94% of the companies listed in the same industry.
  • PHI1's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.68.
  • With a Price/Forward Earnings ratio of 17.36, PHI1 is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of PHI1 indicates a somewhat cheap valuation: PHI1 is cheaper than 67.19% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of PHI1 to the average of the S&P500 Index (28.06), we can say PHI1 is valued slightly cheaper.
Industry RankSector Rank
PE 16.93
Fwd PE 17.36
PHI1.DE Price Earnings VS Forward Price EarningsPHI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PHI1 is valued a bit cheaper than the industry average as 70.31% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHI1 is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 51.48
EV/EBITDA 12.05
PHI1.DE Per share dataPHI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • PHI1's earnings are expected to grow with 13.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.02%
EPS Next 3Y13.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for PHI1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KONINKLIJKE PHILIPS NV

FRA:PHI1 (2/13/2026, 7:00:00 PM)

26.41

-0.35 (-1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)05-06
Inst Owners44.83%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap25.43B
Revenue(TTM)17.83B
Net Income(TTM)895.00M
Analysts73.33
Price Target27.26 (3.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.35
Dividend Growth(5Y)216.55%
DP36.65%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.15%
Min EPS beat(2)14.1%
Max EPS beat(2)22.2%
EPS beat(4)4
Avg EPS beat(4)22.4%
Min EPS beat(4)14.1%
Max EPS beat(4)31.04%
EPS beat(8)4
Avg EPS beat(8)5.12%
EPS beat(12)6
Avg EPS beat(12)7.99%
EPS beat(16)7
Avg EPS beat(16)8.07%
Revenue beat(2)0
Avg Revenue beat(2)-2.61%
Min Revenue beat(2)-2.82%
Max Revenue beat(2)-2.4%
Revenue beat(4)0
Avg Revenue beat(4)-2.29%
Min Revenue beat(4)-2.82%
Max Revenue beat(4)-1.96%
Revenue beat(8)0
Avg Revenue beat(8)-2.85%
Revenue beat(12)1
Avg Revenue beat(12)-2.52%
Revenue beat(16)2
Avg Revenue beat(16)-1.84%
PT rev (1m)-1.52%
PT rev (3m)-0.19%
EPS NQ rev (1m)-15.5%
EPS NQ rev (3m)-15.5%
EPS NY rev (1m)-0.33%
EPS NY rev (3m)-0.56%
Revenue NQ rev (1m)3.12%
Revenue NQ rev (3m)3.69%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.59%
Valuation
Industry RankSector Rank
PE 16.93
Fwd PE 17.36
P/S 1.43
P/FCF 51.48
P/OCF 21.89
P/B 2.32
P/tB N/A
EV/EBITDA 12.05
EPS(TTM)1.56
EY5.91%
EPS(NY)1.52
Fwd EY5.76%
FCF(TTM)0.51
FCFY1.94%
OCF(TTM)1.21
OCFY4.57%
SpS18.52
BVpS11.38
TBVpS-0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham Number19.99
Profitability
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROCE 7.33%
ROIC 5.16%
ROICexc 6.02%
ROICexgc 20.88%
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
FCFM 2.77%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.24%
ROIC(5y)N/A
ROICexc(3y)3.72%
ROICexc(5y)N/A
ROICexgc(3y)12.84%
ROICexgc(5y)N/A
ROCE(3y)4.62%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-1.31%
ROICexc growth 3YN/A
ROICexc growth 5Y-4.82%
OM growth 3YN/A
OM growth 5Y-5.59%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Debt/EBITDA 2.72
Cap/Depr 59.38%
Cap/Sales 3.75%
Interest Coverage 5.63
Cash Conversion 45.59%
Profit Quality 55.2%
Current Ratio 1.32
Quick Ratio 0.94
Altman-Z N/A
F-Score7
WACC6.42%
ROIC/WACC0.8
Cap/Depr(3y)53.03%
Cap/Depr(5y)53.41%
Cap/Sales(3y)3.68%
Cap/Sales(5y)4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.45%
EPS 3Y17.92%
EPS 5Y-5.53%
EPS Q2Q%15.25%
EPS Next Y-2.32%
EPS Next 2Y5.02%
EPS Next 3Y13.51%
EPS Next 5Y7.17%
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%-1.22%
Revenue Next Year2.83%
Revenue Next 2Y3.55%
Revenue Next 3Y4.91%
Revenue Next 5Y3.79%
EBIT growth 1Y15922.2%
EBIT growth 3YN/A
EBIT growth 5Y-5.03%
EBIT Next Year63.55%
EBIT Next 3YN/A
EBIT Next 5Y17.05%
FCF growth 1Y-43.86%
FCF growth 3YN/A
FCF growth 5Y-22.31%
OCF growth 1Y-25.32%
OCF growth 3YN/A
OCF growth 5Y-15.14%

KONINKLIJKE PHILIPS NV / PHI1.DE FAQ

What is the ChartMill fundamental rating of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PHI1.DE.


What is the valuation status for PHI1 stock?

ChartMill assigns a valuation rating of 4 / 10 to KONINKLIJKE PHILIPS NV (PHI1.DE). This can be considered as Fairly Valued.


How profitable is KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

KONINKLIJKE PHILIPS NV (PHI1.DE) has a profitability rating of 2 / 10.


How financially healthy is KONINKLIJKE PHILIPS NV?

The financial health rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 1 / 10.


Can you provide the dividend sustainability for PHI1 stock?

The dividend rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 0 / 10 and the dividend payout ratio is 36.65%.